Format

Send to

Choose Destination
Eur J Haematol. 2016 Apr;96(4):360-6. doi: 10.1111/ejh.12597. Epub 2015 Jul 3.

Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.

Author information

1
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
2
Hamilton Regional Laboratory Medicine Program, Hamilton Health Science, Hamilton, ON, Canada.
3
Department of Oncology, McMaster University, Juravinski Hospital, Hamilton, ON, Canada.
4
Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada.
5
Molecular Genetics Laboratory, London Health Sciences Centre, London, ON, Canada.
6
Population Health Research Institute, Hamilton Health Sciences, McMaster University; McMaster University, Hamilton, ON, Canada.
7
Population Genomics Program, Chanchlani Research Centre, McMaster University; McMaster University, Hamilton, ON, Canada.
8
Department of Clinical Epidemiology and Biostatistics, McMaster University; McMaster University, Hamilton, ON, Canada.
9
Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.

Abstract

OBJECTIVES:

Achieving a major molecular response (MMR) is the goal of imatinib therapy for chronic myeloid leukemia. However, the association between gender, BCR-ABL transcript type, and age with MMR is not well understood and often controversial.

METHODS:

We retrospectively analyzed 166 patients who have been treated with imatinib for up to 10 yr.

RESULTS:

Men had a lower MMR rate than women (63.3% vs. 81.6%, P = 0.006) and a shorter time to relapse (median 354 vs. 675 d, P = 0.049), while patients with b3a2 or with both b3a2 and b2a2 break point transcripts had higher MMR rate than those with b2a2 (81.8%, 77.1% vs. 60.7%, P = 0.023 for b3a2 vs. b2a2, P = 0.043 for both vs. b2a2). A striking difference was found between men with b2a2 and women with both b2a2 and b3a2 in terms of MMR rate (43.8% vs. 88.9%), MMR rate within 6 months (7.1% vs. 62.5%) and the time to MMR (median d 493 vs. 159, P = 0.036).

CONCLUSIONS:

Both gender and BCR-ABL transcript, but not age, were significantly associated with the molecular response. Men with b2a2 represent a less favorable group in their response to imatinib treatment and may need alternative therapy regimen and closer monitoring.

KEYWORDS:

BCR-ABL; chronic myeloid leukemia; gender; imatinib; major molecular response

PMID:
26059983
DOI:
10.1111/ejh.12597
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center